Abstract:Cyclin-dependent kinase like 5 (CDKL5) is a serine-threonine kinase highly enriched in mammalian neurons. CDKL5 is located on the X-chromosome and its loss-of-function leads to a severe neurodevelopmental disorder called CDKL5 deficiency disorder (CDD). CDKL5 phosphorylates microtubule-associated protein MAP1S and regulates its binding to microtubules. How MAP1S phosphorylation affects microtubule function is not well understood. To address this question, we generated MAP1S phosphomutant mice, in which the CDKL5 phosphorylation sites S786 and S812 are mutated to Alanine (MAP1S S786/812A or MAP1S SA). Using a microtubule co-sedimentation assay, we showed that dynein binding to microtubules is severely reduced in CDKL5 knockout (KO) and MAP1S SA brains. Time-lapse imaging in primary neurons showed impaired dynein motility in both Cdkl5 KO and MAP1S SA. Dynein-driven cargo transport was affected in mutant neuron dendrites, including the delivery of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. We next studied tubulin tyrosination in Cdkl5 KO and MAP1S SA neurons and found that both mutants had a reduced tubulin tyrosination when compared to WT neurons. Since dynein-dynactin has a higher affinity for tyrosinated microtubules, we hypothesized that reduced tyrosination in MAP1S phosphomutant mice could be the mechanistic cause of impaired dynein motility. In support of this, we show that upon expression of tubulin tyrosine kinase TTL, we rescued dynein motility defects in MAP1S phosphomutant neurons. Hippocampal neurons derived from MAP1S SA mice revealed a significant reduction in spine density and synapses, and altered spine morphology. Finally, behavioral phenotyping of MAP1S phosphomutant mice showed increased anxiety, impaired motor performance, social and memory deficits, mirroring to some extent the clinical manifestations present in CDD patients. Our results reveal MAP1S phosphorylation to be an important contributor to dynein-mediated transport and synapse formation.

Tumor Suppressor Protein CYLD Regulates Morphogenesis of Dendrites and Spines

Cylindromatosis drives synapse pruning and weakening by promoting macroautophagy through Akt-mTOR signaling

The Tumor Suppressor CYLD Regulates Microtubule Dynamics and Plays a Role in Cell Migration

Deubiquitinase CYLD regulates excitatory synaptic transmission and short-term plasticity in the hippocampus

The Tumor Suppressor Cyld Controls Epithelial Morphogenesis and Homeostasis by Regulating Mitotic Spindle Behavior and Adherens Junction Assembly

CYLD Regulates Spindle Orientation by Stabilizing Astral Microtubules and Promoting Dishevelled-Numa-dynein/dynactin Complex Formation

Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila.

CYLD Mediates Ciliogenesis in Multiple Organs by Deubiquitinating Cep70 and Inactivating HDAC6.

CYLD Negatively Regulates Hippo Signaling by Limiting Hpo Phosphorylation in Drosophila.

CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration.

Coordinated Regulation of Dendrite Arborization by Epigenetic Factors CDYL and EZH2.

Tumour Suppressor Cyld is A Negative Regulator of the Mitotic Kinase Aurora-B

CYLD Regulates Angiogenesis by Mediating Vascular Endothelial Cell Migration.

Ubiquitin Ligase TRIM32 Promotes Dendrite Arborization by Mediating Degradation of the Epigenetic Factor CDYL

Potential Role for the Tumor Suppressor CYLD in Brain and Notochord Development.

Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency

Cell-autonomous reduction of CYFIP2 changes dendrite length, dendritic protrusion morphology, and inhibitory synapse density in the hippocampal CA1 pyramidal neurons of 17-month-old mice

TC10β/CDC42 GTPase activating protein is required for the growth of cortical neuron dendrites.

NudC-like Protein 2 Regulates the LIS1/dynein Pathway by Stabilizing LIS1 with Hsp90

CDKL5's role in microtubule-based transport and cognitive function

Deubiquitinating Enzyme CYLD Negatively Regulates the Ubiquitin-Dependent Kinase Tak1 and Prevents Abnormal T Cell Responses